Pomerantz Law Firm Investigates Claims Against Inspire Medical Systems Over Securities Fraud Concerns.

Pomerantz Law Firm is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (INSP) regarding potential securities fraud or unlawful business practices. The investigation follows the company's reduction of its full-year revenue outlook and diluted net income per share on August 4, 2025, which caused the stock price to fall 32.35% on August 5, 2025.

Title: Pomerantz Law Firm Investigates Inspire Medical Systems, Inc. for Potential Securities Fraud

New York, July 2, 2025 — Pomerantz LLP has initiated an investigation on behalf of investors of Inspire Medical Systems, Inc. (INSP), following the company's recent financial outlook reduction and subsequent stock price decline. The investigation aims to determine whether Inspire and its officers or directors have engaged in securities fraud or other unlawful business practices [1].

On August 4, 2025, Inspire Medical Systems announced its second-quarter financial results and revised its 2025 outlook. The company reduced its full-year revenue projection from $940 million - $955 million to $900 million - $910 million and diluted net income per share from $2.20 - $2.30 to $0.40 - $0.50. This adjustment was attributed to slower-than-expected progress in the commercial launch of its next-generation Inspire V neurostimulation system [1].

The stock price of Inspire Medical Systems fell significantly in response to this news. On August 5, 2025, the stock price decreased by $42.04 per share, or 32.35%, closing at $87.91 per share [1].

Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, is renowned for its history of recovering multimillion-dollar damages on behalf of class members. The firm is advising investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to participate in the investigation [1].

The investigation follows a period of strong financial performance for Inspire Medical Systems. In the second quarter of 2025, the company reported total revenue of $217.1 million, an 11% increase year-over-year. Despite a net loss of $3.6 million, the company's stock surged by 3.41% in after-hours trading, reflecting investor optimism [2].

The company's revised guidance indicates that it anticipates a 12-13% revenue growth in 2025, with expectations for acceleration in 2026. Key strategic initiatives include expanding direct-to-consumer marketing efforts and increasing provider capacity. However, the company faces challenges with the implementation of the new Inspire V system, Medicare billing complexities, and potential impacts from GLP-1 weight loss drugs on the sleep apnea market [2].

Investors are advised to closely monitor the developments in this investigation and consider the potential implications for Inspire Medical Systems' stock price and financial outlook. Pomerantz LLP's investigation is an important step in ensuring that investors are fully informed and protected against potential securities fraud.

References
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-inspire-medical-systems-inc-ins-ce7c5ed2d18cf62d
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-inspire-medical-systems-q2-2025-reports-stock-surge-93CH-4169071